top of page


A drug pipeline is the set of drug candidates held by a pharmaceutical company that is collectively under discovery or development at any given point in time. A drug pipeline may be restricted to a particular drug class or extended to the drug discovery process; R&D pipeline (research and development pipeline). Pharmaceutical companies usually have a number of different drugs/compounds in their pipelines which is an important indicator of the value, company size and future prospects. A drug pipeline can include new drugs, variants of existing drugs and new applications of existing drugs (for different indications).


A drug pipeline starts with new drug discoveries and it is important to assess companies' ability to discover new drugs as well as drugs that are currently in the pipeline. The continued prosperity of a pharmaceutical company is dependent on its ability to keep churning out breakthrough new drugs and turning them into commercial successes backed by a growing body of clinical evidence, and by refilling the early stage of the pipeline as drugs move up. There is a mountain of drugs waiting to hit the market and keeping up with their information is quite challenging.


To capture a more complete picture of a pharmaceutical company or as whole of the pharmaceutical industry’s pipeline and effectively gauge the potential clinical and economic impact on patient outcomes and healthcare systems, the monitoring of pipelines of drugs has become an essential function. Various methods to monitor the drug pipelines have been used over the years, some simple while others complex. Common examples when someone would track drug pipelines to augment current processes to monitor new/existing drug developments is to answer crucial questions noted below:


  1. Is it a novel therapy?

  2. Is it an expanded indication?

  3. Is there a generic that may impact another therapy or class of therapies?

  4. Where will it fall in therapy - will it be first-line with significant advantages over the standard of care, or is it another drug offering little difference compared to therapies already on the market?

  5. What type of prescription volume or sales are expected for this medication once it is approved?

  6. What safety and efficacy data can be gleaned from the available clinical trial results?

  7. What designations has the therapy received that may lead to earlier-than-expected approval?

  8. What is the latest innovation in providing access and insight into the formulary decision-making process?


More people are accessing the internet and doing their daily activities on their smartphones. Smartphones play an integral role in our everyday lives and the benefits that come with its use is undeniably growing. This is because there’s ongoing tremendous transformation of technology and use of mobile apps. Now that apps have become a colossal point of attention, smartphone users rely on them in more than one way. 


3P (short form for Pharmaceutical Pipeline Products) app is intelligently created and designed to gain in-depth pharmaceutical pipeline information at your fingertips. It is a one-stop portal to avoid reviewing multiple data feeds, separating the sheep from the goats, and for preparing all the necessary summary data. It provides up-to-date information on pipelines of drugs in clinical development across multiple pharmaceutical companies and therapeutic areas. The information is collected from public domain sources such as company websites, press releases, clinical trials websites as well as various other news outlets focusing on pipeline products. It is solely developed for informational purposes and is independent of any pharmaceutical company involvement or influence. It is an everyday resource for medical affairs professionals across multiple streams and capacities to gain quick and nifty intelligence, benchmarking, broad drug and clinical trials landscape and meaningful pipeline products coverage. It gives you the power to search the way you want, whether you’re just browsing or want to filter a search by pharmaceutical company, therapeutic area, disease, drug target, or mechanism.

bottom of page